Muraminomicin F
Muraminomicin F is a lipopeptide nucleoside antibiotic and MraY inhibitor (IC50 = 8.9 ng/mL). Muraminomicin F exerts antibacterial effects by inhibiting MraY, an essential key enzyme in bacterial cell wall peptidoglycan biosynthesis. Muraminomicin F can be used in research on bacterial infections.
For research use only. We do not sell to patients.
- CAS No.: 695226-94-9
- Formula: C55H87N5O23
- Molecular Weight:1186.30
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Antibiotic Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Lipopeptide |
In Vitro
Muraminomicin F (18 h) exhibits excellent antibacterial activity against various Gram-positive bacteria, including MRSA and PRSP, and its antibacterial activity decreases with the addition of serum[1].
Muraminomicin F strongly inhibits the MraY enzymatic reaction in a cell-free enzyme assay system, with IC50 = 8.9 ng/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Chemical Information
-
CAS No. 695226-94-9
-
Molecular Weight 1186.30
-
Formula C55H87N5O23
-
SMILES
NC[C@H]([C@H](C1)O)O[C@H]1OC([C@@H]2N(C[C@@H]([C@H](N(C2=O)C)C(O)=O)OC(CC(CCCCCCCCCCC)OC(CC(C)CC(O[C@H]3[C@@H]([C@@H]([C@H]([C@@H](O3)CC)OC)OC(CCC(O)=O)=O)OC)=O)=O)=O)C)[C@H]4O[C@@H](N5C(NC(C=C5)=O)=O)C[C@@H]4O
-
Structure Classification
-
Initial Source
Streptosporangium sp.
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Muraminomicin F Related Classifications
HY-N21881 Related Classifications
Powered by Bioz